Aktiesnakken — Juni 2013
-
Enig plex, den frygt havde jeg også. Men man skal bare huske at Lyxumia ikke engang er med i den undersøgelse her. Det har været Victoza, Byetta og Januvia...
-
Det vil virkelig være forskelsbehandling af anden verden at man afviser et stof fordi konkurrenterne har risikoproblemer

-
Ja danske læsser bare ud.. Har hørt rygter om at det er Maj Invest der vil ud (af strategiske årsager)
-
lom vi ved da ikke noget omkring om der er milepæl ved US godkendelse?=
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind